VistaGen Therapeutics Inc (VTGN)

[Fress]

VTGN Looking beyond the standard
of care for anxiety, depression
and other CNS disorders.

Phase 3 is where the rubber meets the road. And market cap starts to exponential move.

VTGN 115 million plus cash in the bank.

VTGN Institutional Shares have skyrocketed to 61% this year.From 7% last year.

Cash runway into 2023 Till product gets Approved



VTGN Phase 3 ready Fast tracked. Social Anxiety Disorder multi billion dollar market

Multiple phase 2's including VistaGen PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment.


World renown psychologists Michael Liebowitz heading VTGN trials is this very valuable resource to VTGN
https://ir.vistagen.com/press-releases/detail/98/vistagen-therapeutics-appoints-dr-michael-liebowitz-to-cns He developed the
Liebowitz scale he is heading all our trials for VTGN
https://nationalsocialanxietycenter.com/liebowitz-sa-scale/


Biogen bets on depression drug in $1.5 billion deal with Sage Therapeutics
https://www.reuters.com/article/us-biogen-sage/biogen-bets-on-depression-drug-in-1-5-billion-deal-with-sage-therapeutics-idUSKBN2871GU


Acceleration Program (CTAP)
Investment Highlights.
Three Differentiated Clinical-Stage CNS Drug
Candidates.
• Novel Mechanisms of Action (MOAs).
• Favorable Safety Results in All Studies to Date.
• Therapeutic Potential for Phase 3 depression drug in Large Global Mental.
Health and Neurology Markets.
• Multiple NDA-Enabling and Phase 2 Clinical
Catalysts.
• Growing Global Partnership and Licensing Interest.

Anxiety Disorders
PH94B
Depression Disorders
PH10
Neurological Disorders
AV-101

Three differentiated clinical-stage CNS drug candidates
each with a novel mechanism of action, favorable
safety results in all studies to date, and therapeutic
potential in multiple large therapeutic indications
Potential to be a first-in-class, fast-acting, acute treatment of
anxiety for adults with Social Anxiety Disorder and several
other anxiety disorders with inadequate treatment options
Potential stand-alone rapid-onset antidepressant
without side effects and safety concerns of ketaminebased therapy
Potential oral NMDAR-focused prodrug for depression and
multiple neurological indications with adjunctive probenecid.

16 indications in the Pipeline:
https://www.vistagen.com/pipeline


VTGN Anticipated Study Catalysts:
1. Successful Phase 2 program completed; preparing for pivotal Phase 3 clinical development.
2. AffaMed Therapeutics has exclusive rights to develop and commercialize in certain markets in Asia.
3. Preparing for Phase 2A program.
4. Assessing for potential Phase 2A program
5. Successful Phase 2A program completed; preparing for Phase 2B program
6. Assessing for Phase 1B to support potential Phase 2A

Social Anxiety Disorder Affects as many as
20 million people just in the USA
giving a speech
meeting new people
presenting at work
eating/drinking in front of others
interviewing for a job

Current Standard of Care for SAD is Inadequate
Limited treatment options highlight significant unmet need
No FDA-Approved, Fast-Acting, As-Needed Treatment for SAD


Antidepressants (2 SSRIs, 1 SNRI)
Slow onset, chronic administration
May worsen anxiety initially
Significant potential side effects
Nausea and vomiting, weight gain,
somnolence and sexual
dysfunction
Potential drug-drug interaction

Benzodiazepines, Beta Blockers
Addiction risk
Significant potential side effects
Nausea and vomiting, blurred
vision, dizziness, sedation,
confusion and cognitive
impairment



Oral Antidepressants:
• Often do not work; slow to work
– Initial ADT effective in 1 of 3 patients1
– May take 4 to 6 weeks or more for
antidepressant effects
• Significant potential side effects
– Anxiety, sexual dysfunction,
insomnia, dizziness, nausea and
vomiting, headache, sweating

VTGN looking to disrupt depression and anxiety markets globally tens of billions in potential revenue.

VTGN Presentation 2021
https://d1io3yog0oux5.cloudfront.net/_ae1a415cb3c61248d04df87a65dbdb13/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+Version+2021_02_02.pdf



VTGN Pipeline:
https://www.vistagen.com/pipeline


VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

Anxiety depression peers:
$CMPS 2 billion market cap early clinical trials. 190 million cash
$MMEDF 1.2 billion market cap.
$SAGE 3 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 357 million market cap Phase 3 ready. (nasdaq)
115 million in cash

Depression and anxiety one of the most sought after sector in biotech large population of people in the world are depressed.


VTGN 56 million shares traded up from $2.00=$3.18 2 days late last week.

VTGN 16.5 million shares traded last 2 days down from 3.18-2.05 this monday and Tuesday.


VistaGen initiated with Buy at Jefferies $6.00-$8.00 this year 6 days ago.

Buying this stock is helping to fight mental illness anyone shorting this stock is going to lose!!!

$VTGN